The site offers search capability that allows people to learn what type of cancer the clinical trial focuses on, and what phase the trial is currently in.

With a commitment to top-tier research and cancer clinical trials, OSF HealthCare brought on Jun Zhang, MD, PhD, vice president of Oncology Research. Dr. Zhang, under the leadership of James McGee, MD, president and founding director of OSF Cancer Institute, will lead the expansion of clinical trial offerings at OSF Cancer Institute in Peoria.

As of late May 2026, nearly 10 clinical trials are accepting new patients, and more expected to launch in the coming months.

This website launch will help reduce anxiety and stress for people who are looking for cancer resources, providing them an opportunity of hope, in what can be one of the most challenging times.

To view all current clinical trials, please visit the OSF HealthCare Cancer Institute clinical trials website.  

"The most exciting thing that's going on right now, is that some of the most common genetic mutations we know of in pancreatic cancer, are finally having drugs that seem to work against them," says Robert McWilliams, MD, a medical oncologist and the Deputy Director of OSF HealthCare Cancer Institute. "They're in clinical trials right now, but we may see drug approvals as early as this year for these new therapies called KRAS inhibitors. Almost all pancreatic cancer tumors have those mutations. If these drugs are as promising and work as well as we hope, it should make a tremendous difference for pancreatic cancer."

Why this moment matters in pancreatic cancer treatment

Historically, treatment options for pancreatic cancer have advanced slowly compared to other cancers.

"Pancreatic cancer treatment hasn't evolved as quickly as I'd like. We've had more complex chemotherapy regimens that work incrementally better," Dr. McWilliams says. "Trying to put those together into a plan for patients using more neoadjuvant therapies (giving chemotherapy to shrink a tumor before surgery) is something we've done a lot more of in the last few years."

Even with incremental improvements, outcomes have remained challenging – largely because of how pancreatic cancer behaves.

The challenge of a “silent” disease

Pancreatic cancer, one of the deadliest forms of gastrointestinal cancer, is often diagnosed late, when treatment options are more limited. According to 2015-2021 data from the National Cancer Institute, only 13.3% of people survived five or more years after being diagnosed with pancreatic cancer. Nearly 68,000 people were diagnosed with pancreatic cancer in 2025, almost 52,000 of them died from the disease.

"One of the things that's most challenging about pancreatic cancer, is that it can be there without causing specific symptoms. Even though a lot of people with advanced pancreatic cancer do have symptoms commonly, it is a very difficult cancer to detect early," Dr. McWilliams says. "Because of that, oftentimes people present with advanced or metastatic disease.”

Therapeutic cancer vaccines are also in development right now. Promising results from post-operative mRNA-based vaccines have suggested an immune response is possible, and patients may have better outcomes. More trials are in progress to evaluate this further.  

Targeting KRAS: A long-standing goal

According to the Lustgarten Foundation, the largest private funder of pancreatic cancer research in the world, KRAS mutations are central to the disease.

KRAS is a gene that helps control when cells grow and divide. Normally, it works like a switch, turning growth on when the body needs it, and off when it doesn’t. But when KRAS mutates, that switch can get stuck in the “on” position, causing cells to grow nonstop and eventually form cancer.

While KRAS mutations are found in about 11% of all cancers, pancreatic cancer depends on it more than almost any other. In fact, more than 90% of pancreatic ductal adenocarcinomas – the most common type of pancreatic cancer – have a KRAS mutation. That’s why researchers see KRAS as one of the most important and promising targets in the fight against pancreatic cancer.

One of the biggest challenges right now is creating drugs that can shut down the KRAS mutations most seen in pancreatic cancer, especially KRAS-G12D, which shows up in nearly half of all cases. Another key goal is developing treatments that can target several KRAS mutations at the same time. The good news: researchers are actively working on it, with more than 60 RAS-focused drugs currently in development.

New drugs moving through late-stage trials

According to Revolution Medicines, Inc., a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, the U.S. Food and Drug Administration (FDA) has granted a non-transferrable voucher for its drug daraxonrasib (RMC-6236) under the FDA’s Commissioner’s National Priority Voucher pilot program.

Daraxonrasib is being studied in two global Phase 3 clinical trials: RASolute 302 in patients with previously treated metastatic pancreatic ductal adenocarcinoma and RASolve 301 in patients with previously treated metastatic non-small cell lung cancer.

Symptoms that should not be ignored

Even with promising advances, early detection remains critical.

"One of the things is called painless jaundice. If you turn yellow (jaundice), and you're not having abdominal pain, that is a classical sign for pancreatic cancer," Dr. McWilliams points out. "The most common symptom people notice is weight loss. Most of us are trying to lose weight at any moment in time, but sometimes it's a little too easy and the weight starts dripping off. When that happens, that's something to say 'hey, that's great!' But maybe I should get that checked out."

Reducing cancer risk and improving outcomes

Dr. McWilliams says lifestyle choices can play an important role in reducing cancer risk and improving outcomes after diagnosis:

• Don’t smoke cigarettes
• Don’t vape
• Avoid drinking alcohol
• Maintain a healthy lifestyle, including a healthy weight and regular physical activity

Those diagnosed with cancer tend to do better when they engage in more physical exercise. Regular activity can also help protect against other health concerns, including heart disease, neurological disorders and chronic illness.

Video Interview Clips

Leading the charge for cancer care across the region, OSF HealthCare Cancer Institute in Peoria, Illinois, will be offering two ovarian cancer clinical trials for patients.

Clinical trial #1 | GOG 3115

The first trial, which launched in early September 2025, gives select ovarian cancer patients the option to receive an antibody drug conjugate (ADC) that targets specific cancer cells. OSF Cancer Institute will be a part of a cooperative group trial with the GOG Partners program, including multiple sites across the United States.

Michelle Rowland, MD, a gynecologic oncologist with OSF HealthCare, says it will allow for lower dosing, which is an improvement from traditional chemotherapy. This creates fewer side effects, while still being more effective.

"Recently in patients who have had their ovarian cancer recur, we've noted that we have a new drug called mirvetuximab soravtansine with Carboplatin, which works really well in those patients. This is now a trial looking at using this drug in cancer patients with a new diagnosis," Dr. Rowland explains. “This changes what the standard of care is and hopefully improves the responses we're getting and lessening the side effects of their treatment. This will be for patients who are newly diagnosed with ovarian cancer and require chemotherapy."

Common side effects for chemotherapy patients with ovarian cancer:

• Nausea 
• Fatigue 
• Neuropathy (numbness and tingling in hands and feet)
• Bone pain 

Dr. Rowland says OSF Cancer Institute is currently looking for patients with a new ovarian cancer diagnosis for the upcoming trial.

Any new ovarian cancer patient who has not received chemotherapy before would be eligible to try this new drug. 

Clinical trial #2

A second study, which is a national cooperative group trial, is set to offer new treatments for patients who have already undergone ovarian cancer treatment. This is for patients who did well during the treatment, but their cancer came back. 

"These treatments typically involve some of the antibody drug conjugates, but also immunotherapy and combinations of those medications. This gives patients new options they might not see," Dr. Rowland says. "So, for someone who is seen in our system, or seen elsewhere and wants a different treatment option, that will be open here." 

The second trial is expected to launch in late 2025, as OSF HealthCare plans to open additional trials for patients.

Ovarian cancer common facts

For a long time, ovarian cancer has been called the "silent killer." Dr. Rowland wants to dispel that myth, because there are signs and symptoms to look out for, she says. 

Ovarian cancer symptoms:

• Abdominal bloating
• Changes in bowel habits, such as constipation
• Pelvic or abdominal pain
• Lack of appetite
• Feeling full after a few bites of food
• Constantly feeling the need to urinate

"Those are the most common and can be related to a lot of different things. So, if you're having these symptoms, we encourage patients to reach out to their doctor,” Dr. Rowland says.

For breast cancer patients, to be eligible for genetic testing, there are a few guidelines people need to meet. For ovarian cancer, all it takes to receive genetic testing is to have the disease. This is because a larger number of ovarian cancer patients will have a genetic mutation, roughly 15-20%, Dr. Rowland says. 

Robotic-assisted surgeries are an option for select surgeries at OSF HealthCare. Surgeons can use the brand-new da Vinci 5 robotic system by Intuitive. Dr. Rowland says she has seen a benefit for ovarian cancer patients since using the new technology. 

An ovarian cancer survivor group is having a walk at the OSF Cancer Institute on Saturday, September 20. This gives a way for people to support ovarian cancer survivors and learn more about the disease. More information about the 2025 Teal Butterfly Blessings Ovarian Cancer Awareness Walk can be found here.

For more information about gynecologic cancer services and resources at OSF, visit the OSF HealthCare website.

Video Interview Clips